FDA nixes unapproved gout treatment; Interpol at work in Russia;

> The FDA has ordered a halt to the marketing of unapproved single-ingredient oral colchicine, a gout treatment. FDA release

> In Russia, Interpol has begun a large-scale anti-counterfeiting operation. Article

> Varichem Pharma in Zimbabwe has become the third sub-Saharan Africa company to gain WHO prequalification for a medicines product. Article

> BioMimetic is bringing the manufacture of its first U.S. product in-house via a $20-million investment to double the footprint of its Nashville-area facility. Story

> Medicago, a maker of virus-like particle vaccines, held a groundbreaking ceremony last week in Research Triangle Park, NC, for a commercial grade facility. Medicago release

Suggested Articles

AbbVie will soon own Allergan’s prized Botox franchise, and along with its roughly $4 billion in sales, it will get a new $176 million plant.

Merck KGaA has big plans for a site in Switzerland where it intends to knit together biologics development and manufacturing. 

The FDA has found some issues with Biocon’s small molecule plant in Bengaluru, India.